Phathom Pharmaceuticals Inc [PHAT] stock is trading at $18.08, up 10.45%. One of the good ways to gauge the recent performance is if the stock’s short-term value is rising or falling. The PHAT shares have gain 6.86% over the last week, with a monthly amount glided 24.01%, and seem to be holding up well over a long-time horizon.
From an analyst’s perspective:
Phathom Pharmaceuticals Inc [NASDAQ: PHAT] stock has seen the most recent analyst activity on December 12, 2025, when Raymond James initiated its Strong Buy rating and assigned the stock a price target of $28. Previously, Barclays started tracking the stock with Equal Weight rating on December 09, 2025, and set its price target to $16. On February 14, 2025, Cantor Fitzgerald initiated with an Overweight rating and assigned a price target of $23 on the stock. Stifel started tracking the stock assigning a Buy rating and suggested a price target of $24 on May 03, 2024. Needham reiterated its recommendation of a Buy and raised its price target to $26 on January 05, 2024. H.C. Wainwright started tracking with a Buy rating for this stock on August 09, 2023, and assigned it a price target of $28. In a note dated May 11, 2023, Evercore ISI upgraded an Outperform rating on this stock.
Phathom Pharmaceuticals Inc [PHAT] stock has fluctuated between $2.21 and $18.31 over the past year. Currently, Wall Street analysts expect the stock to reach $22.4 within the next 12 months. Phathom Pharmaceuticals Inc [NASDAQ: PHAT] shares were valued at $18.08 at the most recent close of the market. An investor can expect a potential return of 23.89% based on the average PHAT price forecast.
Analyzing the PHAT fundamentals
Phathom Pharmaceuticals Inc [NASDAQ:PHAT] reported sales of 147.19M for the trailing twelve months, which represents a growth of 202.74%. Gross Profit Margin for this corporation currently stands at 0.87% with Operating Profit Margin at -1.45%, Pretax Profit Margin comes in at -1.87%, and Net Profit Margin reading is -1.87%. To continue investigating profitability, this company’s Return on Assets is posted at -1.14, Equity is 0.77 and Total Capital is -1.45. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of-0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 16.95 points at the first support level, and at 15.82 for the second support level. However, for the 1st resistance point, the stock is sitting at 18.65, and for the 2nd resistance point, it is at 19.22.
Ratios To Look Out For
For context, Phathom Pharmaceuticals Inc’s Current Ratio is 2.23. Also, the Quick Ratio is 2.19, while the Cash Ratio stands at 1.45. Considering the valuation of this stock, the price to sales ratio is 8.74.
Transactions by insiders
Recent insider trading involved Breedlove Robert Charles, Principal Accounting Officer, that happened on Nov 03 ’25 when 524.0 shares were sold. Principal Accounting Officer, Breedlove Robert Charles completed a deal on Sep 05 ’25 to sell 461.0 shares. Meanwhile, Principal Accounting Officer Breedlove Robert Charles sold 1692.0 shares on Jul 16 ’25.
